Andere Sprachen Ascelia Pharma AB

Aktien

A2H81X

SE0010573113

ACE

Markt geschlossen - Nasdaq Stockholm Andere Börsenplätze 17:29:39 02.05.2024			% 5 Tage	% 1. Jan.
12,34 ^SEK	+16,64 %		-1,59 %	+266,17 %

02.05.	Ascelia Pharma AB (publ) erreicht erfolgreich den primären Endpunkt mit starken Hauptergebnissen in der Orvigance Phase 3 Studie	CI
10.04.	Ascelia Pharma meldet den Abschluss der SPARKLE-Bildauslesung und erwartet die ersten Ergebnisse in der ersten Maihälfte 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Ascelia Pharma Successfully Meets Primary Endpoint with Strong Headline Results in Orviglance Phase 3 Study	02.05.
Ascelia Pharma AB Successfully Meets Primary Endpoint with Strong Headline Results in Orvigance Phase 3 Study	02.05.
Ascelia Pharma Draws Down SEK 15 Million Second Tranche Under Existing Loan Facility	18.04.
Ascelia Pharma Reports SPARKLE Image Reading Completion and Expects Headline Results First Half of May 2024	10.04.
Ascelia Pharma Reports SPARKLE Image Reading Completion and Expects Headline Results First Half of May 2024	10.04.
Annual Report 2023: Solid Progress with Orviglance Phase 3 Patient Recruitment Completed and Headline Results Expected by May 2024	08.04.
Notice of Annual General Meeting in Ascelia Pharma AB	27.03.
Ascelia Pharma Q4 2023 - On track with easing financial pressure	12.02.
Ascelia Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	09.02.
Q4 and Full Year Report 2023: Strengthened Financial Position Ahead of SPARKLE Phase 3 Study Headline Results in May	09.02.
Ascelia Pharma Secures Financing of up to SEK 35 Million	04.02.
Orviglance Review Article Published in Investigative Radiology	24.01.
Nomination Committee Appointed for AGM 2024 in Ascelia Pharma AB	24.01.
Ascelia Pharma Announces Start of Image Reading Phase and Re-confirms Phase 3 SPARKLE Results by May 2024	07.12.
Ascelia Pharma AB Announces Start of Image Reading Phase and Re- Confirms Phase 3 SPARKLE Results by May 2024	07.12.
Change in Number of Shares and Votes in Ascelia Pharma AB	30.11.
Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 13 November 2023	13.11.
Ascelia Pharma resolves on conversion of series C shares into ordinary shares for delivery to participants in incentive program	09.11.
QUARTERLY REPORT Q3 2023: Re-evaluation of SPARKLE Phase 3 Study Images Progresses According to Plan	08.11.
Ascelia Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Ascelia Pharma AB

Aktien

A2H81X

SE0010573113

ACE

Andere Sprachen

Filter